TSLP and chronic rhinosinusitis with nasal polyps: In this study, we employed NMA to synthesize data from 13 RCTs (n = 2304), systematically evaluating—for the first time—the comparative efficacy of a TSLP inhibitor (tezepelumab) versus conventional Th2‐targeted biologics (dupilumab, omalizumab, and mepolizumab) in CRSwNP.